Under construction – not a live service

Skip to content

Frontlight Research

Institution

Centre Hospitalier Universitaire de Lille

Lille, FranceWebsite

Also known as: CHRU de Lille · CHU de Lille · Centre Hospitalier Régional et Universitaire de Lille

635running trials
238closed trials
47,977publications (OpenAlex)

Running trials

Not yet recruiting
Perioperative Yoga Therapy and Endometriosis Surgery
NCT07765680· University Hospital, Lille· Source
Not yet recruiting
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
NCT06726330· Centre Oscar Lambret· Source
Not yet recruiting
Evaluation of an Intensified Systematic Screening for Congenital Hypothyroidism in Premature Newborns
NCT07425028· University Hospital, Lille· Source
Not yet recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source
Not yet recruiting
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
NCT07718529· Phase 4· Assistance Publique Hopitaux De Marseille· Source
Not yet recruiting
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
NCT07738887· Phase 2· The Lymphoma Academic Research Organisation· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source
Not yet recruiting
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
NCT07576452· Phase 4· University Hospital, Clermont-Ferrand· Source
Not yet recruiting
Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial
NCT07915037· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· Phase 2· Hoffmann-La Roche· Source
Not yet recruiting
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
NCT07700446· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source
Not yet recruiting
A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
2026-526355-62-00· Phase 3· Pfizer Inc.· Source
Not yet recruiting
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source
Not yet recruiting
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· Phase 3· Almirall, S.A.· Source
Not yet recruiting
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
NCT07915765· University Hospital, Lille· Source
Not yet recruiting
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
NCT07376447· iVascular S.L.U.· Source
Not yet recruiting
Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)
NCT07872852· University Hospital, Bordeaux· Source
Not yet recruiting
Efficacy and Safety Evaluation of iNstroke 5F Aspiration Catheter for Thrombectomy
NCT07571954· iVascular S.L.U.· Source
Not yet recruiting
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
2026-525367-40-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Not yet recruiting
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
NCT07929740· Phase 1· Kura Oncology, Inc.· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
NCT07818356· Phase 4· University Hospital, Toulouse· Source
Recruiting
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732· Phase 3· Novo Nordisk A/S· Source
Not yet recruiting
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
NCT07568782· University Hospital, Lille· Source
Not yet recruiting
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· Phase 3· University Hospital, Rouen· Source
Recruiting
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
2024-519511-33-00· Phase 2· Centre Hospitalier Universitaire De Montpellier· Source
Recruiting
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source
Recruiting
Switch to Ofatumumab and Level of Immunoglobulins
NCT07625800· University Hospital, Lille· Source
Not yet recruiting
A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer
2025-523276-23-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
Study of 18FET PET in functional pituitary adenomas with indeterminate MRI findings
2025-523829-17-00· Phase 2· Centre Hospitalier Universitaire De Lille· Source
Not yet recruiting
Evaluation of the Axomove Therapy Medical Device to Facilitate Adapted Physical Activity for Patients With Obesity
NCT07903025· Axomove· Source
Not yet recruiting
Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial
2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source
Not yet recruiting
Evaluate the superiority of Treatment with RAvulizumab vs plasma exchange during the first episode or a relapse In acute neuromyelitis optica (NMO) patients: a national, multicentric, randomised trial
2026-526632-39-00· Phase 3· Les Hopitaux Universitaires De Strasbourg· Source
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
NCT07545512· University Hospital, Clermont-Ferrand· Source
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Not yet recruiting
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Incyte Corp.· Source
Recruiting
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
2025-523285-25-00· Phase 3· AstraZeneca AB· Source
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· Phase 2· AstraZeneca AB· Source
Not yet recruiting
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
NCT07721363· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer
NCT07828938· Fondation Hôpital Saint-Joseph· Source
Not yet recruiting
Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Juxtarenal Abdominal Aortic Aneurysm
NCT07441564· University Hospital, Rouen· Source
Not yet recruiting
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
2023-507010-27-00· Phase 3· Assistance Publique Hopitaux De Paris· Source

Showing 50 of 635.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Withdrawn
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422· Phase 2· Novartis Pharmaceuticals· Source
Completed
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer.
2025-523984-39-00· Phase 2· Gilead Sciences Inc.· Source
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Completed
Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)
NCT06984328· Phase 2· Genmab A/S· Source
Active, not recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203· Phase 2· Iovance Biotherapeutics, Inc.· Source
Completed
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DIVE-Follow up)
2025-522261-30-00· Phase 1/2· Centre Hospitalier Universitaire De Lille· Source
Not yet recruiting
Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma
NCT06933966· Phase 2· Centre Leon Berard· Source
Completed
A multicentre, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of BP1.4979 in adult patients with essential tremor
2024-517987-46-00· Phase 2· Bioprojet Pharma· Source
Completed
C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05896163· Phase 1/2· Pfizer Inc.· Source
Completed
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source
Completed
Characterization of Immune Response in Participants from a Posdinemab Study
2024-514634-20-00· Phase 1· Janssen Cilag International· Source
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522· Phase 2· Amgen· Source
Completed
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment
NCT05066607· Phase 2· Intergroupe Francophone Du Myelome· Source
Completed
Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE
NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren’s Disease
2024-512986-15-00· Phase 2· Kiniksa Pharmaceuticals GmbH· Source
Completed
ALS Phase II Study of NX210c
NCT06365216· Phase 2· Axoltis Pharma· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Active, not recruiting
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751· Phase 2· Noema Pharma AG· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391· Phase 1· Microbiotica Ltd· Source
Completed
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
NCT06444477· University Hospital, Bordeaux· Source
Completed
Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trial
NCT04667078· Phase 4· Fondation A De Rothschild· Source
Active, not recruiting
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217· Phase 1· Novartis Pharmaceuticals· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Active, not recruiting
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
NCT05901194· Phase 1/2· Assistance Publique - Hôpitaux de Paris· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Terminated
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
NCT06488911· Phase 3· Intercept Pharmaceuticals· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)
NCT06424262· Cochlear· Source
Completed
Inflammatory Response in Children Suffering From Tethered Cord
NCT07611058· University Hospital, Lille· Source
Completed
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
NCT06088654· Phase 1/2· Innate Pharma· Source
Completed
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy
2023-509615-92-00· Phase 2· Hopital Fondation Adolphe De Rothschild· Source
Active, not recruiting
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067· Phase 3· Erasca, Inc.· Source
Completed
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288· Phase 3· Areteia Therapeutics Inc.· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· H. Lundbeck A/S· Source
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· Phase 3· Eli Lilly and Company· Source
Completed
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006)
2023-505520-61-00· Phase 2/3· Merck Sharp & Dohme LLC· Source
Completed
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)
2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118· Phase 3· Sanofi· Source
Withdrawn
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT05839145· Institut de Myologie, France· Source
Completed
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· Phase 3· Ab Science· Source
Completed
A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer
NCT04916002· Phase 2· Regeneron Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· Phase 3· Amgen Inc.· Source
Terminated
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
NCT06268574· Phase 2· Ryvu Therapeutics SA· Source
Completed
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia with or without NPM1 Mutation (RIVER-52)
2023-505910-10-00· Phase 2· Ryvu Therapeutics S.A.· Source

Showing 50 of 238.

Registry name variants (56)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Centre Hospitalier Universitaire De Lille
Lille Cedex, 59037
379 trials
Centre Hospitalier Universitaire de Lille
Lille, 59000
281 trials
CHU Lille
Lille, 59000
58 trials
CHU de Lille
Lille, 59037
53 trials
CHRU Lille
Lille, 59037
36 trials
CHRU de Lille
Lille, 59037
35 trials
CHU Lille
Lille Cedex, 59037
3 trials
- NCT05826509SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
- NCT05260528CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
- 2022-500905-42-00Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1
CHU Lille - Institut Coeur Poumon
Lille, Nord 59037
3 trials
- NCT07144280A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- NCT06119581A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT04451044Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting
CHU Lille - Institut Cœur Poumon
Lille, 59000
3 trials
- NCT07529275Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms
  Contact: Jonathan Prof. SOBOCINSKI
- NCT05788120Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock
  Contact: Benoit BRASSART
- NCT04931771Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization
Centre Hospitalier Regional et Universitaire de Lille
Lille, 59037
2 trials
- NCT06353854Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
  Contact: ANTONY TURPIN, MD
- NCT00005584Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
CHU de Lille - Institut Coeur Poumon
Lille, 59037
2 trials
- NCT07771465A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
  Contact: Kardigan Clinical Trial Team
- NCT07210723A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
  Contact: Kardigan Clinical Trial Team
CHU LILLE - Centre Hospitalier Universitaire de Lille
Lille, 59000
2 trials
- NCT07455422A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
  Contact: Florence Nosal
- NCT06523374A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer
  Contact: Florence Nosal
Institut Coeur Poumon - CHU Lille
Lille Cedex, 59037
2 trials
- 2023-504897-39-00A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours
- NCT02273375Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Lille - CHU
Lille
2 trials
- NCT07234058Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
  Contact: Pr Arnaud SCHERPEREEL
- NCT06053099A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
  Contact: Alexis CORTOT
Centre Hospitalier Universitaire de Lille (CHU Lille)
Lille, 59000
1 trial
- NCT06268574Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
Centre Hospitalier Universitaire de Lille - CIC
Lille, 59037
1 trial
- NCT05889572Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis
Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon
Lille
1 trial
- NCT07630545A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
  Contact: Prof David Davos, Professor (principal investigator)
Centre Hospitalier Universitaire de Lille, medical oncology department
Lille, 59037
1 trial
- NCT06790706IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Centre Hospital Universitaire de lille
Lille, 59000
1 trial
- NCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
  Contact: Emmanuel Boleslawski, pr
CHRU de Lille - service de Médecine Interne
Lille
1 trial
- NCT04276701Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
CHRU de Lille - service de neurologie
Lille
1 trial
- NCT05209815Safety of Exposure to Natalizumab During Pregnancy
CHRU Lille - Centre Hospitalier Universitaire de Lille
Lille
1 trial
- NCT06832371Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
CHRU Lille, Cœur Poumon Institute
Lille, Nord 59000
1 trial
- NCT04020263Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
  Contact: Gilles LEMESLE, MD-PhD
CHRU Lille - Institut Coeur Poumon
Lille, 59000
1 trial
- NCT02649426A Study of the ReCor Medical Paradise System in Clinical Hypertension
CHU de Lille - Institut Coeur Poumons
Hellemmes-Lille
1 trial
- NCT03974022Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
CHU de Lille - Institut Cœur-Poumons
Lille, 59000
1 trial
- NCT06833138Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control
  Contact: Christelle MARQUIE, MD
CHU de Lille - service d'Hématologie
Lille
1 trial
- NCT06444477Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
CHU Lille (Expert center)
Lille, 59000
1 trial
- NCT03453268Impact of Reducing Antihypertensive Treatment on Mortality in Frail Subjects With Low Systolic Blood Pressure (SBP).
CHU Lille - Gastroenterology
Lille, 59000
1 trial
- NCT06104631A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms
  Contact: Salvatore Modica
CHU Lille - Institut Coeur Poumon (Site 9100)
Lille, Nord 59037
1 trial
- NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
  Contact: Study Coordinator
Clinical neurophysiology, CHU Lille
Lille, France 59037
1 trial
- NCT04693221Optimization of the Parameters of Vagal Nerve Stimulation
Département de Neurologie - CHRU Lille
Lille, 59037
1 trial
- NCT04690998Outcome Measures and Biomarkers in a Cohort of Spinal Muscular Atrophy Type III/ IV Patients
Hop Salengro - Chu Lille
Lille
1 trial
- NCT05269069Impact of Rheumatoid Arthritis on Body Composition, Bone Marrow Adiposity and Bone Mineral Density: a Case-control Study
Hospitalario Universitario (CHU) de Lille
Lille, 59000
1 trial
- NCT05698732Coroflex® ISAR NEO PMCF Study
  Contact: koldobika García San Román, MD, PhD
Institut Cœur Poumon - CHRU de Lille
Lille, 59037 Cedex
1 trial
- NCT07872852Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)
  Contact: Nicolas LAMBLIN, MD, PhD
Institut Coeur Poumon, CHU de Lille
Lille, France 59000
1 trial
- NCT06097260Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Institut Cœur Poumon - CHU Lille
Lille
1 trial
- NCT05752552Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
  Contact: Alexis Cortot, Prof. MD
Le centre hospitalier universitaire de Lille
Lille, 59000
1 trial
- NCT07235514Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2
  Contact: Lise Laclautre
Service de néonatalogie, CHRU de Lille
Lille, 59000
1 trial
- NCT07411261PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants
  Contact: Kevin Le Duc
Service de Neurophysiologie - unité de médecine du Sommeil - CHU Lille
Lille
1 trial
- NCT06808464New Approach in the Study of the Autonomic Nervous System Through Cardiac Variability in Sleep Apnea Syndrome.
  Contact: Philippe Derambure, Pr
Univ. Lille, CHU Lille
Lille
1 trial
- NCT05575167Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
Centre Hospitalier Universitaire de Lille (CHU de Lille)
Lille, 59037
Centre Hospitalier Universitaire de Lille (CHU Lille) - Centre Regional de Pharmacovigilance (CRPV)
Lille, Hauts-de-France 59045
CHRU de LILLE - Claude Huriez
Lille
CHRU de Lille - Hpital Jeanne de Flandre
Lille, 59037
CHRU Lille, Service d'Hématologie Pédiatrique
Lille, 59037
CHRU Lille (Site 1306)
Lille, Nord 59037
CHRU of Lille
Lille, 59037
CHU de LILLE - Bureau des ARCs Gastro - HPDD
Lille, 59037
CHU de Lille - Institut Coeur Poumon /ID# 276868
Lille, Hauts-de-France 59000
CHU de Lille - Rue Michel Polonovski
Lille, Nord 59037
CHU Lille - Institut Coeur Poumon (Site 1005)
Lille, Nord 59037
CHU Lille - Service de pneumologie et d'oncologie thoracique
Lille, Nord 59037
Department of Hematology, CHU Lille
Lille
Institut Coeur Poumon - CHRU de Lille (Site 0252)
Lille, Hauts-de-France 59037
Institut Coeur Poumon - CHRU de Lille (Site 1306)
Lille, Hauts-de-France 59037

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 02ppyfa04 (CC0-1.0)Updated 12 Nov 2026

Report an error

Under construction, not live – Centre Hospitalier Universitaire de Lille: trials and research groups – Frontlight Research